CAR-NK在实体瘤治疗中的研究进展  

Research progress of CAR-NK in the treatment of solid tumors

作　　者：史佳欣 袁青宏 尉丁 蒋建利 边惠洁 南刚 SHI Jiaxin;YUAN Qinghong;WEI Ding;JIANG Jianli;BIAN Huijie;NAN Gang(No.5 Cadet Regiment,School of Basic Medical Sciences,Air Force Medical University,Xi’an 710032,China;National Translational Science Center for Molecular Medicine,Department of Cell Biology,School of Basic Medicine,Air Force Medical University,Xi’an 710032,China)

机构地区：[1]空军军医大学基础医学院学员五大队,西安710032 [2]空军军医大学国家分子医学转化中心,基础医学院细胞生物学教研室,西安710032

出　　处：《生命的化学》2024年第11期2033-2041,共9页Chemistry of Life

基　　金：国家自然科学基金面上项目(82372787);陕西省自然科学基金重点研发计划项目(2023-YBSF-174)。

摘　　要：目前嵌合抗原受体T(chimeric antigen receptor T,CAR-T)在肿瘤尤其是血液肿瘤的治疗方面已经取得了重大的成果,但是在实体瘤治疗领域仍存在较大的困难,如靶向实体瘤困难、无法有效浸润肿瘤组织、实体肿瘤微环境的免疫抑制性等。而嵌合抗原受体NK细胞可能作为CAR-T疗法治疗实体瘤的替代方案,目前已有多项基于CAR-NK的优化研究进入临床试验阶段。本文通过简述CAR-NK细胞疗法的原理、应用、局限和发展,总结了CAR-NK细胞近几年来在实体瘤治疗中的研究进展,为未来的研究和临床应用提供参考。At present,chimeric antigen receptor T(CAR-T)cell therapy has made great achievements in the treatment of tumors,especially blood tumors,but there are still great difficulties in the field of solid tumors,such as targeting solid tumors,the inability to effectively infiltrate tumor tissue,and the immune inhibition of the solid tumor microenvironment.Chimeric antigen receptor NK cells may be an alternative to CAR-T therapy for solid tumors,and a number of optimization studies based on CAR-NK have entered the clinical trial stage.By briefly describing the principle,application,limitation and development of CAR-NK cell therapy,this paper summarized the research progress of CAR-NK cells in the treatment of solid tumors in recent years,and provided a reference for future research and clinical application.

关 键 词：CAR-NK细胞 免疫治疗 恶性肿瘤 实体瘤 NK细胞 

分 类 号：R730.51[医药卫生—肿瘤]